Sept 10, 2024 Partner Entos Online Publication in Cell “Safe and Effective Delivery of DNA & RNA Using PLVs”

Sept 10, 2024 Partner Entos Online Publication in Cell “Safe and Effective Delivery of DNA & RNA Using PLVs”

Read theCell paper, published September 10, 2024, titled Safe and Effective Delivery of DNA and RNA Using Proteolipid Vehicles. DOI: 10.1016/j.cell.2024.07.023    Also available on ScienceDirect Citation: Brown, D.W., Wee, P., Bhandari, P., Bukhari, A., Grin, L., Vega, H., Hejazi, M., Sosnowski, D., Ablack, J., Clancy, E.K., et

Read more

Aug 6, 2024 Aegis and Partner Entos announced first participant dosed in phase 1/2 clinical trial of Covigenix VAX-002 COVID-19 booster vaccine

Aug 6, 2024 Aegis and Partner Entos announced first participant dosed in phase 1/2 clinical trial of Covigenix VAX-002 COVID-19 booster vaccine

Press Release Entos Pharmaceuticals Announces First Participant Dosed in Clinical Trial for COVID-19 Vaccine Booster First participant dosed in the Covigenix VAX-002 Phase 1/2 Study to Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA Booster Vaccine Against SARS-CoV-2 August 06, 2024 08:00 AM Eastern Daylight Time

Read more

March 19, 2024 Aegis Life Receives Investment to Continue Development of DNA-Encoded Therapeutic Antibodies Against Infectious Diseases Using the Fusogenix PLV Platform

March 19, 2024 Aegis Life Receives Investment to Continue Development of DNA-Encoded Therapeutic Antibodies Against Infectious Diseases Using the Fusogenix PLV Platform

Press Release Aegis Life receives a program-related investment of $4.45M from the Bill & Melinda Gates Foundation This investment supports the continuation of the ongoing research collaboration between Aegis Life and Entos Pharmaceuticals Aegis Life is developing novel DNA-based encoded antibody therapeutics against HIV and malaria using

Read more